OpGen Inc (NASDAQ:OPGN) stock is trading higher following two SEC filings from the precision medicine company.

The company has received an advanced payment of €750,000 related to the sale of certain Unyvero A50 systems by Curetis to a strategic partner.

The strategic partner may, in its discretion, purchase additional Unyvero A50 systems from Curetis while the parties continue to pursue a potential strategic transaction.

The company intends to use the advance payment to fund Curetis’ and Ares Genetics’ operations while negotiating with the strategic partner.

OpGen also announced a Preferred Stock Purchase Agreement. It signed an agreement with a certain investor to acquire 1,000 shares priced at $1,000 each, with gross proceeds of $1 million. 

The Private Placement was conducted in connection with the negotiation of a potential strategic transaction involving the company and the Investor. 

OpGen stock is gaining on heavy volume, with a session volume of 14.9 million shares traded, compared to the trailing 100-day volume of 2.24 million shares.

Price Action: OPGN shares are up 578.6% at $2.28 during the premarket session on the last check Thursday.